TEPEZZA Approved In Brazil For The Treatment Of Active Thyroid Eye Disease
Portfolio Pulse from Happy Mohamed
Horizon Therapeutics' TEPEZZA has been approved by the Brazilian Health Regulatory Agency (ANVISA) for the treatment of active thyroid eye disease (TED). This marks the first approval of TEPEZZA outside the United States, addressing a significant unmet need for those living with this progressive autoimmune disease.
June 26, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Horizon Therapeutics' TEPEZZA has been approved in Brazil for the treatment of active thyroid eye disease, marking its first approval outside the US.
The approval of TEPEZZA in Brazil expands Horizon Therapeutics' market reach and addresses a significant unmet need for those living with active thyroid eye disease. This is likely to have a positive impact on the company's stock price in the short term as it demonstrates the company's commitment to the global rare disease community and potential for further international expansion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100